Funding for this research was provided by:
FP7 Science in Society (HEALTH-305937)
Received: 2 October 2019
Accepted: 3 March 2020
First Online: 15 April 2020
Ethics approval and consent to participate
: The protocol has been approved by national regulatory agencies (in accordance with the ethical standards laid down in the Declaration of Helsinki as revised in 2013), by the institutional boards for clinical research of all participating institutions, and by the national ethics review committees of the countries involved in the study (when applicable). Referral ethical board: Vall d’Hebron University Hospital Ethical Committee on Clinical Research with Drugs (EUDRACT no. 2016-003789-21). All patients provide written informed consent, whereby the researcher will explain to each patient the nature of the study; its purposes, procedures, and expected duration; the potential risks and benefits related to participating; and any inconvenience that may occur.
: Not applicable.
: The authors declare that they have no competing interests.